which has just reported phase 1 results with its first two NLRP3 inhibitors, and ZyVersa Therapeutics with preclinical-stage candidate IC 100 that is being considered for multiple sclerosis.

The NLRP3 inflammasome is implicated in a host ... in preclinical development but being eyed as a possible treatment for multiple sclerosis.

Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called ...

RIPK1 and NLRP3, to become overactive. This overactivity leads to excessive cell death and people with a mutation in the TBK1 gene often experience inflammation in multiple organs. Led by Jelena ...

SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company ...